Envestnet Asset Management
PTCT icon

Envestnet Asset Management’s PTC Therapeutics PTCT Stock Holding History

Envestnet Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$431K Buy
5,289
+1,990
+60% +$144K ﹤0.01% 4182
2026
Q1 		$225K Buy
+3,299
New +$234K ﹤0.01% 4449
2022
Q4 		– Sell
-5,183
Closed -$260K – 4035
2022
Q3 		$260K Buy
+5,183
New +$254K ﹤0.01% 3441

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Envestnet Asset Management's PTCT Position: Q2 2026 in Review

Envestnet Asset Management increased its PTC Therapeutics (PTCT) stake by 60% in Q2 2026, buying an estimated $144K and bringing the position to 5,289 shares worth $431K. The position accounts for ﹤0.01% of the portfolio, ranked #4182.

Envestnet Asset Management first reported a position in PTCT in Q3 2022 and has held it in 3 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Envestnet Asset Management held 5,289 shares of PTC Therapeutics worth $431K as of Q2 2026.
  • Envestnet Asset Management bought 1,990 PTC Therapeutics shares in Q2 2026, an estimated $144K.
  • PTC Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4182 holding.
  • Envestnet Asset Management first reported a position in PTC Therapeutics in Q3 2022 and has held it in 3 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.